Abstract: TH-PO0619
Managing CKD Better: Where Do We Stand?
Session Information
- CKD: Clinical - Guidelines, Biomarkers, Progression, Procedures, Outcomes, and More
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Yee, LaiLai Wyut, Epsom and Saint Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom
- Raman, Sagarika, Epsom and Saint Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom
- Alomari, Waleed Abdallah Dheif Allah, Epsom and Saint Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom
- Wahba, Mona, Epsom and Saint Helier University Hospitals NHS Trust, Carshalton, England, United Kingdom
Group or Team Name
- St Helier CKD team
Background
Chronic Kidney Disease (CKD) is associated with cardiovascular morbidity, progression to kidney failure, and reduced quality of life. Evidence-based management slows CKD progression and improves outcomes. The KIDGO guidelines recommend use of ACE inhibiors (ACEi)/ ARBs, SGLT2 inhibitors, statins, and, more recently, Finerenone in appropriate patients. This audit assessed current practice in CKD management against KDIGO recommendations.
Methods
A retrospective audit of 358 patients with CKD stage 1-5 attending renal outpatient clinic in a sigle centre between September and October 2023 with a follow up period of 18 months. Demographics, comorbidities, stages of CKD, and treatment with ACEi/ARBs, SGLT2 inhibitors, statins, and Finerenone were collected. Data on proteinuria, and the use of antiplatelet in peoples with established cardiovascular disease, was collected. Outcomes were compared against KDIGO guideline standards.
Results
56% of 358 patients were male and 65% were aged over 60 years. 74% had CKD stages 3 to 4 with 44% of them living with Diabetes and 47% with proteinuria.
Among proteinuric patients, 47% were prescribed SGLT2 inhibitors, and of these, 70% demonstrated a reduction in proteinuria of greater than 15% from baseline. ACEi or ARBs were prescribed in 76% of proteinuric patients. Statins were prescribed in 62% of the overall cohort, with higher uptake in patients with diabetic kidney disease (81%).
The uptake of using Finerenone was very limited, with only 2.5% of people with diabetic kidney disease patients receiving this therapy following NICE approval 6 months prior to data collection. Antiplatelet prescribing was appropriate in all patients with established cardiovascular disease.
Conclusion
Our audit demonstrated reasonable adherence to KIDGO guidelines in the use of ACEi/ARB, SGLT2 inhibitors and statin in people with CKD. Further efforts to implement NICE recommendation on the use of finerone in CKD is needed given increasing evidence on its cardiovascular risk reduction.